Abstract:Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovitis and the destruction of small joints. Emerging evidence shows that immunoglobulin D (IgD) stimulation induces T-cell activation, which may contribute to diseases pathogenesis in RA. In this study, we investigated the downstream signaling pathways by which IgD activated T cells as well as the possible role of IgD in the T–B interaction. Peripheral blood mononuclear cells were isolated from peripheral blood of healthy controls and RA patients. We demonstrated that IgD activated T cells through IgD receptor (IgDR)-lymphocyte-specific protein tyrosine kinase (Lck)-zeta-associated protein 70 (ZAP70)/phosphatidylinositol 3-kinase (PI3K)/nuclear factor kappa-B (NF-κB) signaling pathways; IgD-induced CD4+ T cells promoted the proliferation of CD19+ B cells in RA patients. A novel fusion protein IgD-Fc-Ig (composed of human IgD-Fc domain and IgG1 Fc domain, which specifically blocked the IgD–IgDR binding) inhibited the coexpression of IgDR and phosphorylated Lck (p-Lck) and the expression levels of p-Lck, p-ZAP70, p-PI3K on CD4+ T cells, and decreased NF-κB nuclear translocation in Jurkat cells. Meanwhile, IgD-Fc-Ig downregulated the expression levels of CD40L on CD4+ T cells as well as CD40, CD86 on CD19+ B cells in RA patients and healthy controls. It also decreased the expression levels of CD40L on CD4+ T cells and CD40 on CD19+ B cells from spleens of collagen-induced arthritis (CIA) mice and reduced IL-17A level in mouse serum. Moreover, administration of IgD-Fc-Ig (1.625–13 mg/kg, iv, twice a week for 4 weeks) in CIA mice dose-dependently decreased the protein expression levels of CD40, CD40L, and IgD in spleens. IgD-Fc-Ig restrains T-cell activation through inhibiting IgD-IgDR-Lck-ZAP70-PI3K-NF-κB signaling, thus inhibiting B-cell activation. Our data provide experimental evidences for application of IgD-Fc-Ig as a highly selective T cell-targeting treatment for RA.

Through an ITIM-independent mechanism the FcγRIIB blocks B cell activation by disrupting the colocalized microclustering of the B cell receptor and CD19.

Tgf-Beta-Induced Regulatory T Cells Directly Suppress B Cell Responses Through A Noncytotoxic Mechanism

FcγRIIB-mediated dissociation of BCR-CD19 microclusters and hyperreactivity of lupus B cells (HUM7P.303)

Antigen-induced oligomerization of the B cell receptor is an early target of Fc gamma RIIB inhibition.

Transmembrane domain dependent inhibitory function of FcγRIIB

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies

FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

TIGIT-Fc fusion protein alleviates murine lupus nephritis through the regulation of SPI-B-PAX5-XBP1 axis-mediated B-cell differentiation

Impairment on the Lateral Mobility Induced by Structural Changes Underlies the Functional Deficiency of the Lupus-Associated Polymorphism FcγRIIB-T232

Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization

An IgD-Fc-Ig fusion protein restrains the activation of T and B cells by inhibiting IgD-IgDR-Lck signaling in rheumatoid arthritis

FcγRIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape

PI3K- and PTEN-Governed PIP2 and PIP3 Equilibrium Regulates the Activation and Function of B Cells Through Dock2 Controlled Growth of Antigen Receptor Microclusters

FcγRIIB-I232T Polymorphic Change Allosterically Suppresses Ligand Binding

Fc Receptor–like 1 Intrinsically Recruits C-Abl to Enhance B Cell Activation and Function

IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors

Effect of BAFF blockade on the B cell receptor repertoire and transcriptome in a mouse model of systemic lupus erythematosus

Distinct Integrin Activation Pathways for Effector and Regulatory T Cell Trafficking and Function

Monovalent Fc Receptor Blockade by an Anti–fcγ Receptor/albumin Fusion Protein Ameliorates Murine ITP with Abrogated Toxicity

Antibody Fc-receptor FcεR1γ stabilizes cell surface receptors in group 3 innate lymphoid cells and promotes anti-infection immunity

Defining the Immunological Phenotype of Fc Receptor-Like B (FCRLB) Deficient Mice: Confounding Role of the Inhibitory FcγRIIb.